JP7204670B2 - シクロデキストリン及びブスルファンを含有する組成物 - Google Patents

シクロデキストリン及びブスルファンを含有する組成物 Download PDF

Info

Publication number
JP7204670B2
JP7204670B2 JP2019560139A JP2019560139A JP7204670B2 JP 7204670 B2 JP7204670 B2 JP 7204670B2 JP 2019560139 A JP2019560139 A JP 2019560139A JP 2019560139 A JP2019560139 A JP 2019560139A JP 7204670 B2 JP7204670 B2 JP 7204670B2
Authority
JP
Japan
Prior art keywords
busulfan
cyclodextrin
pharmaceutical composition
solution
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019560139A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020518608A (ja
JP2020518608A5 (cg-RX-API-DMAC10.html
Inventor
ディー． ピプキン，ジェイムズ
Original Assignee
サイデックス・ファーマシューティカルズ・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サイデックス・ファーマシューティカルズ・インコーポレイテッド filed Critical サイデックス・ファーマシューティカルズ・インコーポレイテッド
Publication of JP2020518608A publication Critical patent/JP2020518608A/ja
Publication of JP2020518608A5 publication Critical patent/JP2020518608A5/ja
Priority to JP2022212559A priority Critical patent/JP7597778B2/ja
Application granted granted Critical
Publication of JP7204670B2 publication Critical patent/JP7204670B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019560139A 2017-05-03 2018-05-02 シクロデキストリン及びブスルファンを含有する組成物 Active JP7204670B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022212559A JP7597778B2 (ja) 2017-05-03 2022-12-28 シクロデキストリン及びブスルファンを含有する組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762500970P 2017-05-03 2017-05-03
US62/500,970 2017-05-03
PCT/US2018/030728 WO2018204535A1 (en) 2017-05-03 2018-05-02 Composition containing cyclodextrin and busulfan

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022212559A Division JP7597778B2 (ja) 2017-05-03 2022-12-28 シクロデキストリン及びブスルファンを含有する組成物

Publications (3)

Publication Number Publication Date
JP2020518608A JP2020518608A (ja) 2020-06-25
JP2020518608A5 JP2020518608A5 (cg-RX-API-DMAC10.html) 2021-06-17
JP7204670B2 true JP7204670B2 (ja) 2023-01-16

Family

ID=64014433

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019560139A Active JP7204670B2 (ja) 2017-05-03 2018-05-02 シクロデキストリン及びブスルファンを含有する組成物
JP2022212559A Active JP7597778B2 (ja) 2017-05-03 2022-12-28 シクロデキストリン及びブスルファンを含有する組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022212559A Active JP7597778B2 (ja) 2017-05-03 2022-12-28 シクロデキストリン及びブスルファンを含有する組成物

Country Status (10)

Country Link
US (2) US20180318249A1 (cg-RX-API-DMAC10.html)
EP (1) EP3618825A4 (cg-RX-API-DMAC10.html)
JP (2) JP7204670B2 (cg-RX-API-DMAC10.html)
KR (1) KR20190141244A (cg-RX-API-DMAC10.html)
CN (1) CN110831588B (cg-RX-API-DMAC10.html)
AU (1) AU2018263924B2 (cg-RX-API-DMAC10.html)
BR (1) BR112019023074A2 (cg-RX-API-DMAC10.html)
CA (1) CA3062308A1 (cg-RX-API-DMAC10.html)
MX (2) MX2019013053A (cg-RX-API-DMAC10.html)
WO (1) WO2018204535A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109078005B (zh) * 2018-08-07 2021-11-26 江苏领航生物科技有限公司 一种白消安组合物及其制备方法和应用
KR20220083773A (ko) * 2019-10-18 2022-06-20 이뮤노믹 쎄라퓨틱스, 인크. 암 항원을 포함하는 개선된 lamp 구축물
CN113679852B (zh) * 2021-09-13 2022-11-15 天津师范大学 一种水溶性主客体复合物及其制备与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005530866A (ja) 2002-05-10 2005-10-13 雲清 劉 有機医薬とβ−シクロデキストリン誘導体との複合体、およびその調製方法
JP2006503047A (ja) 2002-09-13 2006-01-26 サイデックス・インコーポレイテッド 誘導シクロデキストリンにより安定化された水性フィル組成物を含有するカプセル
JP2006316076A (ja) 1999-01-13 2006-11-24 Cydex Inc スルホアルキルエーテルシクロデキストリンを基剤とする放出制御固形医薬製剤

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3426011A (en) 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR927003645A (ko) 1990-05-21 1992-12-18 후지다 히로미찌 씨클로덱스트린 유도체
US5180716A (en) 1990-08-01 1993-01-19 The Regents Of The University Of California Cyclodextrin complexes for neuraxial administration of drugs
US5430057A (en) 1993-09-30 1995-07-04 Board Of Regents, The University Of Texas System Parenteral busulfan for treatment of malignant disease
US5874418A (en) 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
ES2257795T3 (es) 1997-07-01 2006-08-01 Pfizer Products Inc. Procedimiento para producir una ciclodextrina.
TWI242015B (en) 1999-11-29 2005-10-21 Akzo Nobel Nv 6-mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block
WO2004022100A1 (en) 2002-08-15 2004-03-18 Yunqing Liu Soild nano pharmaceutical formulation and preparation method thereof
WO2005042584A2 (en) 2003-10-31 2005-05-12 The University Of Kansas Sulfoalkyl ether-alkyl ether cyclodextrin derivatives
US20070020196A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
SI2952197T1 (sl) 2005-10-26 2017-09-29 Cydex Pharmaceuticals, Inc. Sestavki sulfoalkil eter ciklodekstrina in metode priprave le-tega
WO2007062403A2 (en) * 2005-11-28 2007-05-31 Vernon D Rowe Compositions useful for reducing nephrotoxicity and methods of use thereof
US7658913B2 (en) * 2005-11-28 2010-02-09 Verrow Pharmaceuticals, Inc. Compositions useful for reducing nephrotoxicity and methods of use thereof
CN100411688C (zh) * 2006-09-12 2008-08-20 南京师范大学 含有环糊精/多烯紫杉醇包合物的药物组合物及其制备方法
NZ575394A (en) * 2006-10-20 2012-01-12 Icos Corp Compositions of chk1 inhibitors and cyclodextrin
KR101522918B1 (ko) * 2009-05-29 2015-05-27 사이덱스 파마슈티칼스, 인크. 사이클로덱스트린 유도체를 포함하는 주사용 멜팔란 조성물 및 이의 제조 및 사용 방법
AU2013259573B2 (en) * 2012-05-08 2018-02-15 Onyx Therapeutics, Inc. Cyclodextrin complexation Methods for Formulating Peptide Proteasome Inhibitors
CN105726467A (zh) * 2014-12-09 2016-07-06 四川科瑞德制药有限公司 一种白消安注射液及其制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006316076A (ja) 1999-01-13 2006-11-24 Cydex Inc スルホアルキルエーテルシクロデキストリンを基剤とする放出制御固形医薬製剤
JP2005530866A (ja) 2002-05-10 2005-10-13 雲清 劉 有機医薬とβ−シクロデキストリン誘導体との複合体、およびその調製方法
JP2006503047A (ja) 2002-09-13 2006-01-26 サイデックス・インコーポレイテッド 誘導シクロデキストリンにより安定化された水性フィル組成物を含有するカプセル

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GHERMANI, N.E. et al，Molecular reactivity of busulfan through its experimental electrostatic properties in the solid state，Pharmaceutical research，2004年，Vol.21, No.4，pp.598-607
MENUEL, S. et al，Synthesis and inclusion ability of a bis-beta-cyclodextrin pseudo-cryptand towards Busulfan anticancer agent ，Tetrahedron，2007年，Vol.63，pp.1706-1714
PORWANSKI, S. et al，Bis-beta-cyclodextrinyl- and bis-cellobiosyl-diazacrowns: synthesis and molecular complexation behaviors towards Busulfan anticancer agent and two basic aminoacids，Tetrahedron，2009年，Vol.65，pp.6196-6203

Also Published As

Publication number Publication date
MX2019013053A (es) 2020-02-07
US20180318249A1 (en) 2018-11-08
RU2019135196A3 (cg-RX-API-DMAC10.html) 2021-07-28
CA3062308A1 (en) 2018-11-08
MX2023000348A (es) 2023-02-13
EP3618825A4 (en) 2021-01-20
KR20190141244A (ko) 2019-12-23
RU2019135196A (ru) 2021-06-03
EP3618825A1 (en) 2020-03-11
JP2020518608A (ja) 2020-06-25
CN110831588B (zh) 2023-06-27
AU2018263924B2 (en) 2024-07-04
CN110831588A (zh) 2020-02-21
JP2023026562A (ja) 2023-02-24
AU2018263924A1 (en) 2019-11-21
BR112019023074A2 (pt) 2020-06-09
WO2018204535A1 (en) 2018-11-08
US20230255919A1 (en) 2023-08-17
JP7597778B2 (ja) 2024-12-10

Similar Documents

Publication Publication Date Title
JP7597778B2 (ja) シクロデキストリン及びブスルファンを含有する組成物
KR100984197B1 (ko) 아미오다론 및 설포알킬 에테르 사이클로덱스트린을함유하는 제제
AU2008256808A2 (en) Compositions useful for reducing nephrotoxicity and methods of use thereof
US20090023683A1 (en) Complexes comprising zoledronic acid and cyclodextrins
EP1396268B1 (en) Stable oxazaphosphorine-2-mercaptoethanesulphonate formulations
KR20200059221A (ko) 시포니모드를 포함하는 비경구 제형
JP2024051102A (ja) アセトアミノフェンおよびスルホアルキルエーテルシクロデキストリンを含む製剤
WO2013026694A1 (en) Pharmaceutical compositions comprising voriconazole
KR20180111948A (ko) 오리타반신 제제
RU2787621C2 (ru) Композиция, содержащая циклодекстрин и бусульфан
RU2772384C9 (ru) Составы, содержащие ацетаминофен и сульфоалкиловый эфир циклодекстрина
RU2772384C2 (ru) Составы, содержащие ацетаминофен и сульфоалкиловый эфир циклодекстрина
US20250186342A1 (en) Antiemetic combinations

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210430

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210430

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220419

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220714

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220916

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221017

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221206

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221228

R150 Certificate of patent or registration of utility model

Ref document number: 7204670

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250